UCB (OTCMKTS:UCBJF) Shares Gap Down – Here’s Why

UCB SA (OTCMKTS:UCBJF)’s share price gapped down before the market opened on Friday . The stock had previously closed at $340.0375, but opened at $320.89. UCB shares last traded at $338.24, with a volume of 4 shares trading hands.

Wall Street Analyst Weigh In

UCBJF has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of UCB in a report on Monday, December 8th. Barclays reaffirmed an “overweight” rating on shares of UCB in a research note on Tuesday, January 6th. Stephens reiterated an “overweight” rating on shares of UCB in a research report on Thursday, January 15th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of UCB in a research note on Monday. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy”.

UCB Stock Performance

The stock’s fifty day moving average price is $304.20 and its 200 day moving average price is $276.83. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.